Neurotech, Neuromodulation, Alzheimers.
period of years. As one of few examples that target cognitive decline, FDA awarded “Breakthrough Device” status to Boston Scientific’s Vercise deep brain stimulation (DBS) systems in people aged 65 years and older with mild probable AD. Functional Neuromodulation, whose founder led the Johns